BioSpace News Archive

-- Rapid completion of Phase 2 enrollment signals further momentum for the development of rusfertide in polycythemia vera --

Fractyl Announces FDA Breakthrough Device Designation for Revita ® DMR in Insulin-Treated Type 2 Diabetes - REVITA-T2Di study is underway to evaluate the effectiveness of Revita DMR in improving glucose control while reducing or eliminating the need for insulin -

Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and associated drug formulations to safely and effectively destroy various cancers, bacteria and viruses has released the Company’s Quarterly Newsletter which provides updates on the previous quarter and progress on the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study.

Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath ® Laboratory With the acquisition, Castle expects to make available the most comprehensive molecular testing offering for difficult-to-diagnose melanocytic lesions. The Company to host a conference call today at 7:30 a.m. E.T.

MJ Biotech, Inc. (OTC PINK:MJTV), the first shipment to Invest Africa Global of Covid 19 Rapid Test Kit arrived at Namibia, Africa April 23, 2021. The Rapid Test kit is a Nasal Swab test that produces test results in 10 minutes. This is an exciting time for the Company and for Invest Africa Global, as well.

Technology partner, Mannin Research, receives new R&D funding for COVID project and Several Milestones Expected in 2021

Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), developer of novel self-assembling wound care and biosurgical devices, today announced that two clinical case report abstracts of AC5 ® Advanced Wound System will be presented at the upcoming 2021 Symposium on Advanced Wound Care (SAWC).

Presentations highlight the pathogenic role of the CD6-ALCAM pathway, the immunologic impact of modulating this pathway with itolizumab, and pharmacodynamic assays to monitor this in patients

Pyxis Oncology (“Pyxis” or the “Company”) today announced the targets of its three antibody-drug conjugate (ADC) candidates along with additional details and preclinical data supporting the potential of its ADC platform.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the B. Riley Securities’ Virtual Neuroscience Conference being held on April 28 - 29.